Table 2. PFS and OS multivariate analysis by patients’ characteristics.
| Progression free survival | Overall survival | |||||||
|---|---|---|---|---|---|---|---|---|
| Hazard Ratio | 95% CIa | P | Hazard Ratio |
95% CI | P | |||
| Ascites | No | 1.0 | 0.13 | 1.0 | 0.02 | |||
| Yes | 1.6 | 0.86-2.7 | 2.8 | 1.2-6.6 | ||||
| Peritoneal Biopsy | No | 1.0 | <0.01 | 1.0 | 0.04 | |||
| Yes | 0.29 | 0.15-0.58 | 0.33 | 0.11-0.96 | ||||
| Residual mass | No | 1.0 | 0.29 | 1.0 | 0.07 | |||
| Yes | 1.6 | 0.68-3.6 | 2.7 | 0.92-8.2 | ||||
| FIGO Stage | IA+IB | 1.0 | <0.01 | - | - | - | ||
| IC | 1.6 | 0.56-4.6 | 0.38 | - | - | - | ||
| IIB | 6.1 | 1.9-19.1 | <0.01 | - | - | - | ||
| IIA | 4.0 | 1.2-13.3 | 0.03 | - | - | - | ||
| I | - | - | - | 1.0 | 0.01 | |||
| II | - | - | - | 2.1 | 1.2-3.5 | |||
| Capsule rupture | No | 1.0 | 0.70 | 1.0 | 0.48 | |||
| Yes | 0.88 | 0.45-1.7 | 1.4 | 0.56-3.4 | ||||
| Cytology |
Negative /Unknown |
1.0 | 0.15 | 1.0 | 0.61 | |||
| Positive | 1.5 | 0.86-2.7 | 1.3 | 0.54-2.9 | ||||
| Differentiation | G1b | 1 | 0.09 | 1 | 0.92 | |||
| G2-3c/Clear cell | 1.4 | 0.95-2.1 | 1.0 | 0.58-1.8 | ||||
| Histologtic type | Serous | 1.0 | 0.59 | 1.0 | 0.01 | |||
| Mucinous | 0.96 | 0.31-3.0 | 0.75 | 0.65 | 0.07-6.4 | 0.53 | ||
| Clear cell | 1.96 | 0.86-4.1 | 0.54 | 6.0 | 1.7-22.0 | 0.01 | ||
| Endometrioid | 1.31 | 0.56-3.1 | 0.11 | 5.4 | 1.7-16.0 | 0.01 | ||
| others | 17 | 0.47-2.9 | 0.95 | 1.3 | .33-5.5 | 0.68 | ||
| Chemotherapy | PTX+CBP/DDPd | 1.0 | 0.07 | 1.0 | 0.10 | |||
| No | 1.5 | 0.41-5.7 | 0.53 | 1.7 | 0.19-14.7 | .65 | ||
| Other | 2.0 | 1.1-3.9 | 0.24 | 2.6 | 1.1-6.4 | 0.03 | ||
a: CI: Confident interval; b: G1, well differentiated; c:G2, moderately differentiated, G3, poorly differentiated; d: PTX: Paclitaxel, CBP: Carboplatin, DDP: Cisplatin.